Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Boehringer Ingelheim

Tracked across 25 events · 193 articles · First seen Dec 19, 2025 · Last active Sep 23, 2026

Sentiment
25
Attention
6
Events
25
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Boehringer Ingelheim is expanding its global Computational Innovation footprint with a new AI and machine learning center in London, investing £150 million over 10 years to advance pharmaceutical R&D.
Apr 20, 2026 · 6 articles
4 70
Business
Impact: Boehringer Ingelheim entered into a global licensing agreement with Immunitas Therapeutics for a preclinical antibody program, strengthening its immunology pipeline and expanding its portfolio in autoimmune and inflammatory diseases.
May 12, 2026 · 6 articles
3 40
Tech
Impact: Boehringer Ingelheim is the sponsor and developer of BI 3034701; the Phase II trial advances its obesity pipeline, potentially enhancing its market position in the obesity treatment space.
Jul 16, 2026 · 6 articles
1 10
Business
Boehringer Ingelheim announced the launch of PED Essentials, a free online e-learning hub designed to help patient organizations generate, analyze and share high-quality patient experience data (PED). The platform was co-created with patients and subject…
Impact: The privately held biopharmaceutical company launched PED Essentials and co-developed it with patient experts and Patvocates. The move is reputationally positive and supports its regulatory and integrated-evidence strategy, with no material revenue effect.
Sep 17, 2026 · 6 articles
2 60
Business
Impact: Boehringer Ingelheim has entered into a partnership with Sequent Scientific — Alivira Animal Health Limited to expand its sales capabilities and market reach for companion animal products in India.
Jan 22, 2026 · 6 articles
2 30
Business
Impact: Boehringer Ingelheim India Private Limited signed an MoU with NIPER Hajipur to advance pharmaceutical research and education, providing access to its opnMe® platform and strengthening its commitment to India's pharmaceutical education network.
Apr 23, 2026 · 6 articles
4 60
Tech
Impact: Boehringer Ingelheim is collaborating with Suzhou Ribo Life Science Company on the MASH siRNA program, which has reached a significant milestone, advancing its pipeline for liver disease treatments.
May 06, 2026 · 7 articles
4 70
Regulatory
Impact: Boehringer Ingelheim's HERNEXEOS received FDA approval with Guardant360 CDx as its companion diagnostic, marking a significant step in bringing a new targeted therapy to market for HER2-mutant NSCLC patients.
Jun 11, 2026 · 7 articles
0 5
Business
Boehringer Ingelheim, AWARE Germany e.V. and AWARE Trust Zimbabwe launched a multi-year rabies-control initiative in the Tsholotsho District of Zimbabwe under Boehringer Ingelheim's global Stop Rabies program. The project uses a One-Health approach combining dog…
Impact: Boehringer Ingelheim is the lead corporate partner, funding and expanding the Stop Rabies program in Zimbabwe through its animal health business. The initiative supports its vaccine and animal health franchise reputation with limited direct financial effect.
Sep 23, 2026 · 7 articles
2 40
Business
Impact: Boehringer Ingelheim is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
4 40
Accidents
Impact: Acknowledged farmer concerns and is working to secure additional bluetongue vaccine supplies. Increased vaccine demand could boost its revenue.
Aug 11, 2026 · 24 articles
2 10
Business
Cloverleaf Bio, an RNA therapeutics company spun out of Yale University and headquartered in New Haven, Connecticut, closed an upsized and oversubscribed $33 million seed financing round. The round was led by 4BIO Capital and…
Impact: Its venture fund invested in the round, reflecting strategic interest in Cloverleaf's novel RNA therapeutics approach.
Sep 08, 2026 · 6 articles
2 5
Regulatory
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry.…
Impact: One of the nine signatories of the open letter urging EU action on medicine spending, trials and IP protection. Its participation signals shared industry concern over European competitiveness.
Sep 22, 2026 · 6 articles
6 10
Business
Impact: Boehringer Ingelheim is advertising for kidney disease screening with celebrity endorsements, participating in the health and telehealth advertising trend.
Feb 04, 2026 · 6 articles
1 10
Business
Impact: Boehringer Ingelheim participated in the symposium, showing its engagement in green chemistry initiatives.
Jul 20, 2026 · 6 articles
2 30
Tech
Impact: Boehringer Ingelheim is a consortium member. The study's findings could support its use of the NeuLogiq platform in future CNS trials.
Aug 18, 2026 · 6 articles
1 10
Tech
Impact: Boehringer Ingelheim provided support for the global awareness survey and the development of materials sharing its results.
May 05, 2026 · 7 articles
4 10
International
Impact: Boehringer Ingelheim managers are traveling with Friedrich Merz, indicating a focus on deepening cooperation in the pharmaceuticals sector with India.
Jan 11, 2026 · 6 articles
4 40
Business
Impact: Mentioned as a previous partner of Grand Pharmaceutical Group, highlighting the platform's track record but not directly affected by this deal.
Jul 20, 2026 · 11 articles
2 0
Tech
A study published on Sept. 17, 2026 in Science identified the inherited EGFR T790M mutation as a major risk factor for lung cancer, especially in never-smokers. Researchers led by Jaclyn LoPiccolo and Pasi A. Jänne…
Impact: Boehringer Ingelheim's past deal with Hanmi Pharm for olmutinib is mentioned as a historical example of EGFR therapy development challenges.
Sep 17, 2026 · 6 articles
4 0
Tech
A large U.S. study published in the journal Gastro Hep Advances found that daily consumption of sugar-sweetened beverages is associated with a more than doubled risk of stomach (gastric) cancer. Researchers from the Mass General…
Impact: Andrew T. Chan served as a consultant; no direct impact.
Aug 17, 2026 · 20 articles
4 0
Tech
A study led by NYU Langone Health, published in the journal Pediatrics on September 4, 2026, found that prescriptions for GLP-1 weight-loss drugs (Saxenda, Wegovy, Zepbound) among US children aged 8-11 with obesity increased 310-fold…
Impact: Orandi served on advisory board; not directly involved.
Sep 04, 2026 · 7 articles
6 0
Regulatory
Dec 19, 2025 · 7 articles
4 0
Tech
Apr 09, 2026 · 6 articles
4 0
Business
Apr 13, 2026 · 6 articles
United States ↔ Boehringer Ingelheim
United States ↔ Boehringer Ingelheim
ERGEN INTELLIGENCE
Track Boehringer Ingelheim live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.